Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Canadian Natural Resources Ltd. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Canadian Natural Resources Ltd. trades at $42.2 (market cap $86.83B). The key difference: Canadian Natural Resources Ltd. is far larger — about 2.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Canadian Natural Resources Ltd. pays a 4.21% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CNQ | |
|---|---|---|
Market Cap | $39.89B | $86.83B |
Sector | Health | Energy |
52-Week High | $491.22 | $50.55 |
52-Week Low | $278.09 | $29.31 |
Enterprise Value | $38.15B | $98.06B |
Dividend Yield | — | 4.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CNQ trades at $41.81, down 0.17% on the day, with a bullish technical signal and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.85 exceeding the $0.74 estimate. Valuation metrics appear attractive with a P/E of 11.8 and EV/EBITDA of 6.54, while profitability remains high with a net income margin of 24.5% and ROE of 25.81%.
The outlook is positive given consistent earnings outperformance, a 75% analyst buy rating, and strong free cash flow supporting shareholder returns. Key risks include oil price volatility and rising debt levels, but the company's operational stability and dividend yield near 4% provide a cushion for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
